Cubist Systematic Strategies, LLC Bristol Myers Squibb CO Transaction History

Cubist Systematic Strategies, LLC

$15.1 Billion
Q4 2024

A detailed history of Cubist Systematic Strategies, LLC transactions in Bristol Myers Squibb CO stock. As of the latest transaction made, Cubist Systematic Strategies, LLC holds 47,100 shares of BMY stock, worth $2.63 Million. This represents 0.02% of its overall portfolio holdings.

Number of Shares

47,100

Previous 6,040 679.8%

Holding current value

$2.63 Million

Previous $312,000 753.53%

% of portfolio

0.02%

Previous 0.0%

28 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2024 Feb 14, 2025	BUY	$51.92 - $59.94 $2.13 Million - $2.46 Million	41,060 Added 679.8%	47,100 $2.66 Million
Q3 2024 Nov 14, 2024	SELL	$39.66 - $51.75 $34.9 Million - $45.6 Million	-881,127 Reduced 99.32%	6,040 $312,000
Q2 2024 Aug 14, 2024	BUY	$40.25 - $52.99 $35.7 Million - $47 Million	887,167 New	887,167 $36.8 Million
Q4 2023 Feb 14, 2024	BUY	$48.48 - $57.85 $36.3 Million - $43.3 Million	749,012 Added 17104.64%	753,391 $38.7 Million
Q3 2023 Nov 14, 2023	SELL	$57.89 - $64.73 $45.7 Million - $51.1 Million	-788,858 Reduced 99.45%	4,379 $254,000
Q2 2023 Aug 14, 2023	BUY	$63.71 - $70.74 $44.2 Million - $49.1 Million	694,069 Added 699.89%	793,237 $50.7 Million
Q1 2023 May 15, 2023	SELL	$65.71 - $74.53 $21.6 Million - $24.5 Million	-329,308 Reduced 76.86%	99,168 $6.87 Million
Q4 2022 Feb 14, 2023	BUY	$68.48 - $81.09 $29.3 Million - $34.7 Million	428,476 New	428,476 $30.8 Million
Q2 2022 Aug 15, 2022	BUY	$72.62 - $79.98 $12.4 Million - $13.6 Million	170,177 Added 104.35%	333,255 $25.7 Million
Q1 2022 May 16, 2022	SELL	$61.48 - $73.72 $5.04 Million - $6.05 Million	-82,000 Reduced 33.46%	163,078 $11.9 Million
Q4 2021 Feb 14, 2022	BUY	$53.63 - $62.52 $2.55 Million - $2.97 Million	47,566 Added 24.08%	245,078 $15.3 Million
Q3 2021 Nov 15, 2021	BUY	$59.17 - $69.31 $7.98 Million - $9.34 Million	134,815 Added 215.03%	197,512 $11.7 Million
Q2 2021 Aug 16, 2021	SELL	$61.91 - $67.42 $13.7 Million - $14.9 Million	-221,342 Reduced 77.93%	62,697 $4.19 Million
Q1 2021 May 17, 2021	BUY	$59.34 - $66.74 $7.59 Million - $8.53 Million	127,863 Added 81.87%	284,039 $17.9 Million
Q4 2020 Feb 16, 2021	SELL	$57.74 - $65.43 $1.56 Million - $1.77 Million	-27,065 Reduced 14.77%	156,176 $9.69 Million
Q3 2020 Nov 16, 2020	SELL	$57.43 - $63.64 $1.16 Million - $1.28 Million	-20,125 Reduced 9.9%	183,241 $11 Million
Q2 2020 Aug 14, 2020	BUY	$54.82 - $64.09 $8.06 Million - $9.42 Million	146,941 Added 260.42%	203,366 $12 Million
Q1 2020 May 15, 2020	SELL	$46.4 - $67.43 $1.22 Million - $1.78 Million	-26,325 Reduced 31.81%	56,425 $3.15 Million
Q4 2019 Feb 14, 2020	SELL	$49.21 - $64.19 $1.58 Million - $2.06 Million	-32,157 Reduced 27.99%	82,750 $5.31 Million
Q3 2019 Nov 14, 2019	SELL	$42.77 - $50.71 $9.98 Million - $11.8 Million	-233,375 Reduced 67.01%	114,907 $5.83 Million
Q2 2019 Aug 14, 2019	BUY	$44.62 - $49.34 $1.64 Million - $1.82 Million	36,819 Added 11.82%	348,282 $15.8 Million
Q1 2019 May 15, 2019	BUY	$45.12 - $53.8 $13.5 Million - $16.1 Million	300,150 Added 2653.14%	311,463 $14.9 Million
Q4 2018 Feb 14, 2019	SELL	$48.76 - $63.23 $363,652 - $471,569	-7,458 Reduced 39.73%	11,313 $588,000
Q3 2018 Nov 14, 2018	SELL	$55.19 - $62.25 $640,535 - $722,473	-11,606 Reduced 38.21%	18,771 $1.17 Million
Q2 2018 Aug 14, 2018	SELL	$50.53 - $62.98 $822,375 - $1.02 Million	-16,275 Reduced 34.89%	30,377 $1.68 Million
Q1 2018 May 15, 2018	SELL	$59.92 - $68.98 $1.3 Million - $1.5 Million	-21,753 Reduced 31.8%	46,652 $2.95 Million
Q4 2017 Feb 14, 2018	BUY	$59.94 - $65.35 $3.59 Million - $3.91 Million	59,858 Added 700.34%	68,405 $4.19 Million
Q3 2017 Nov 14, 2017	BUY	$55.23 - $63.74 $472,050 - $544,785	8,547	8,547 $545,000

Others Institutions Holding BMY

# of Institutions

2,751

Shares Held

1.57B

Call Options Held

28M

Put Options Held

28.7M

View Full List

About BRISTOL MYERS SQUIBB CO

Ticker BMY
Exchange NYSE
Sector Healthcare
Industry Drug Manufacturers—General
Shares Outstandng 2,126,160,000
Market Cap $119B
Description
Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, and markets biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, neuroscience, and covid-19 diseases. The company's products include Revlimid, an oral immunomodulatory drug for the treatment of multiple my...

More about BMY

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Cubist Systematic Strategies, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Cubist Systematic Strategies, LLC with notifications on news.

Account

Cubist Systematic Strategies, LLC Bristol Myers Squibb CO Transaction History